Publication:
Effects of photodynamic therapy on dermal fibroblasts from xeroderma pigmentosum and Gorlin-Goltz syndrome patients

Loading...
Thumbnail Image
Identifiers
Publication date
2017-09-29
Defense date
Advisors
Tutors
Journal Title
Journal ISSN
Volume Title
Publisher
Impact Journals, LLC
Impact
Google Scholar
Export
Research Projects
Organizational Units
Journal Issue
Abstract
PDT is widely applied for the treatment of non-melanoma skin cancer premalignant and malignant lesions (actinic keratosis, basal cell carcinoma and in situ squamous cell carcinoma). In photodynamic therapy (PDT) the interaction of a photosensitizer (PS), light and oxygen leads to the formation of reactive oxygen species (ROS) and thus the selective tumor cells eradication. Xeroderma pigmentosum (XP) and Gorlin-Goltz Syndrome (GS) patients are at high risk of developing skin cancer in sun-exposed areas. Therefore, the use of PDT as a preventive treatment may constitute a very promising therapeutic modality for these syndromes. Given the demonstrated role of cancer associated fibroblasts (CAFs) in tumor progression and the putative CAFs features of some cancer-prone genodermatoses fibroblasts, in this study, we have further characterized the phenotype of XP and GS dermal fibroblasts and evaluated their response to methyl-d-aminolevulinic acid (MAL)-PDT compared to that of dermal fibroblasts obtained from healthy donors. We show here that XP/GS fibroblasts display clear features of CAFs and present a significantly higher response to PDT, even after being stimulated with UV light, underscoring the value of this therapeutic approach for these rare skin conditions and likely to other forms of skin cancer were CAFs play a major role.
Description
Keywords
Photodynamic therapy, Ultraviolet light, Cancer-associated fibroblasts, Gorlin-goltz syndrome, Xeroderma pigmentosum
Bibliographic citation
Zamarrón, A., García, M., Del Río, M., Larcher, F., & Juarranz, Á. (2017). Effects of photodynamic therapy on dermal fibroblasts from Xeroderma pigmentosum and Gorlin-Goltz syndrome patients. Oncotarget, 8(44), 77385-77399.